SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden, received approvals from the Swedish Medical Products Agency and local ethics committees to initiate a Phase I/II clinical trial of a novel DNA vaccine designed to treat chronically infected hepatitis C virus (HCV) patients. The trial will test Tripep’s proprietary DNA vaccine, ChronVac-C®, administered using Inovio’s MedPulser® DNA Delivery System, in 12 subjects already infected with HCV. The trial will be conducted in Sweden at two Karolinska University Hospitals, the Center for Gastroenterology in Solana and the Infections Clinic in Huddinge, beginning in October 2007.
